LIFE: First positive indication of increased sensor sensitivity in ongoing longevity study — TradingView News

Mar 25, 2025

Bergen, Norway, 25 March - Lifecare ASA (LIFE), a medical sensor companyadvancing product development for the next-generation Continuous GlucoseMonitoring (CGM), announces a first positive indication that the recentlycommunicated enhanced sensor chemistry is demonstrating increased sensitivityalso in real-life settings.

The improved chemistry, previously reported to achieve up to a fivefoldimprovement in sensitivity in laboratory experiments, has now been tested inLifecare's ongoing longevity study in dogs. This study is an essential part ofLifecare's product development process.

The initial in-vivo results show a promising and encouraging trend, aligningwith the earlier in-vitro test results. While previous in-vitro testing refersto laboratory-based experiments, the ongoing in-vivo testing refers to testingin live tissue that provides insight into real-world biological responses andlong-term performance.

Importantly, the testing of the improved chemistry is being conducted as anadditional feature within the broader framework of the ongoing productdevelopment. As such, this additional testing does not impact or delay theprogress of product development in any way.

Significance of sensor sensitivitySensor sensitivity is a key performance parameter for CGM technology,influencing the ability to detect small glucose fluctuations. Previous datafromLifecare (LFC-SEN-001) confirmed that the initial CGM system achieved a MeanAbsolute Relative Difference (MARD) of 9.6%, meeting the standard forclinicallyacceptable accuracy (MARD <10%). The improved chemistry has the potential toenhance accuracy further. While the testing so far provides a firm expectationthat the sensitivity and the MARD will be positively impacted, finalconclusionsin this respect remains subject to further data collection.

"Observing a continued positive trend in the testing and now in live tissuerepresents an exciting step forward. These real-life results reinforce ourconfidence in the potential of our enhanced chemistry. Our team remainsdedicated to refining our CGM technology to ensure the highest precision andreliability for patients," says Joacim Holter, CEO of Lifecare.

Further validation is requiredThe ongoing longevity study in dogs is designed to investigatebiocompatibility,foreign body responses and in general provide product development relatedinformation. The study is not designed to provide collection of data toconcludeon the measurement sensitivity as is, and consequently the current results arehighly encouraging but not conclusive. Further data collection will berequiredto fully validate the impact of the improved chemistry under real-lifeconditions.

Lifecare continues to push the boundaries of CGM innovation and is committedtoconducting further studies to confirm the performance benefits of its improvedsensor chemistry.

Ongoing product developmentThe progress of product development remains very much in line with theforward-looking statements outlined in Lifecare's Q3 and Q4 2024 reports,further underlining the company's consistent and focused developmenttrajectory.Moreover, this progress strengthens Lifecare's preparations for upcomingregulatory testing, which is required to document the features and claims oftheCGM system in support of CE marking and market approval.

About usLifecare ASA is a medical sensor company developing technology for sensing andmonitoring of various body analytes. Lifecare's main focus is to bring thenextgeneration of Continuous Glucose Monitoring ("CGM") systems to market.Lifecareenables osmotic pressure as sensing principle. Lifecare's sensor technology isreferred to as "Sencell" and is suitable for identifying and monitoring theoccurrence of a wide range of analytes and molecules in the human body and inpets.

ContactsFor further information, please contact:

Joacim Holter, CEO, [email protected], +47 40 05 90 40

Renete Kaarvik, CFO, [email protected], +47 94 83 82 42

https://newsweb.oslobors.no/message/642131